Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.1 (chymotrypsin)
 10,938 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The hypothesis that the ADP-sensitive form of phosphorylated Na+, K+-ATPase contains occluded sodium ions has been tested by a procedure which involves (i) modifying the enzyme with alpha-chymotrypsin or N-ethylmaleimide (NEM) so that the ADP-sensitive form is more stable than it is in the native enzyme, (ii) phosphorylating the modified enzyme with ATP in the presence of labelled sodium ions, and (iii) forcing the phosphorylated enzyme rapidly through a cation-exchange column and measuring the labelled sodium in the effluent. The results show that ADP-sensitive phosphoenzyme prepared from alpha-chymotrypsin- or NEM-modified Na+, K+-ATPase is able to carry labelled sodium ions through a cation-exchange resin. This behaviour was not seen with native Na+, K+-ATPase or when phosphorylation was prevented by the omission of magnesium ions or by the substitution of adenylyl(beta, gamma-methylene)diphosphonate (AMP-PCP) for ATP. The occluded sodium ions were rapidly released when the phosphoenzyme was dephosphorylated by ADP. When alpha-chymotrypsin-modified enzyme was phosphorylated by ATP with 1 mM-sodium in the medium, close to three sodium ions were occluded per phospho group. The stoicheiometry at much lower sodium concentrations could not be determined satisfactorily. A consideration of the rate constants of the reactions thought to be involved in the occlusion of sodium and in the release of sodium from the occluded state shows that, so far as they are known, these constants are compatible with the hypothesis that the occluded-sodium form of the phosphoenzyme plays a central role in sodium transport through the pump.
 ...
PMID:The occlusion of sodium ions within the mammalian sodium-potassium pump: its role in sodium transport. 608 5

A novel mucoadhesive drug carrier system has been generated which protects a model polypeptide antigen from degradation by the most abundant intestinal proteases. The enzyme inhibitors antipain, chymostatin and elastatinal, respectively, were covalently attached to the mucoadhesive polymer sodium carboxymethylcellulose (NaCMC) and the inhibitory efficacy of the resulting polymer-inhibitor conjugates was evaluated in vitro. When these inhibitor conjugates were combined with the thiolated polymer polycarbophil-cysteine (PCP-Cys), 95.8 +/- 3.8% (mean +/- SD, n = 3) of the incorporated model antigen ovalbumin (OVA) was protected from enzymatic degradation within 90 min incubation in the presence of an artificial intestinal fluid containing the pancreatic serine proteases trypsin, chymotrypsin and elastase. Replacing the CMC-inhibitor conjugates in the dosage form by unmodified CMC significantly reduced the protective effect to 78.8 +/- 4.7% (mean +/- SD, n = 3), whereas incorporation of the model antigen in a CMC dosage form omitting PCP-Cys protected 72.5 +/- 3.2% (mean +/- SD, n = 3) of OVA from degradation within a 90 min incubation period. Further, the incorporation of PCP-Cys resulted in higher cohesiveness within the dosage form and controlled drug release of the antigen for a time period of more than 9 h. Results suggest that a delivery system combining thiolated polymer and polymer-inhibitor conjugates improves the metabolic stability of the model polypeptide antigen and may therefore be a useful tool for oral protein vaccination.
 ...
PMID:Design and in vitro evaluation of a mucoadhesive oral delivery system for a model polypeptide antigen. 1159 93

Cystine-knot microproteins exhibit several properties that make them highly interesting as scaffolds for oral peptide drug delivery. It was therefore the aim of the study to evaluate the novel clinically relevant cystine-knot microprotein McoEeTI regarding its potential for oral delivery. Additionally, based on the gained results, important features of McoEeTI were improved. Enzymatic degradation was caused by chymotrypsin, trypsin and porcine small intestinal juice whereas McoEeTI was stable towards elastase, membrane bound proteases, pepsin and porcine gastric juice. Only minor McoEeTI degradation was observed during a 24h incubation period in rat plasma. In the presence of various physiological ions about 50% of McoEeTI formed di- and/or trimers. P(app) value of McoEeTI was determined to be (7.4+/-0.4)x10(-6)cm/s. Sodium caprate and polycarbophil-cysteine (PCP-Cys) had no beneficial effect on McoEeTI permeation, whereas the utilization of a chitosan-thiobutylamidine (Chito-TBA) system improved McoEeTI permeation 3-fold. Enzymatic stability could be strongly improved by the utilization of Bowman-Birk-Inhibitor (BBI) as well as PCP-Cys. In conclusion, this study indicates that McoEeTI represents a promising candidate as a novel scaffold for oral peptide drug delivery.
 ...
PMID:Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration. 1707 Jun 61